Inclusion Criteria:  who are undergoing routine phacoemulsification (one eye per patient); who are 21 years or older; who should be able to communicate properly and understand instructions. willing and/or able to comply with the scheduled visits and other study procedures.  Exclusion Criteria:  patients who already participated with their contralateral eye; combined surgery (e.g. combined phacoemulsification and trabeculectomy); patients with an increased risk of developing cystoid macular edema (CME) in the study eye (e.g. diabetes mellitus, previous retinal venous occlusion, or a history of uveitis, macular edema, epiretinal membrane, or previous retinal surgery); patients who developed CME after cataract surgery in the contralateral eye; patients with cystoid macular changes in the study eye at baseline; patients with an increased risk of developing perioperative complications (e.g. Fuchs' endothelial dystrophy); patients with permanent moderate visual impairment in the contralateral eye (decimal visual acuity less than 0.3); patients with a history of steroid induced IOP rise or glaucomatous visual field loss; patients using drugs that reduce or increase the risk of macular edema (e.g., periocular or intraocular corticosteroid, NSAID, or antivascular endothelial growth factor (VEGF) injection; topical corticosteroid or NSAID use; systemic corticosteroids (>= 20mg prednisolon), methotrexate, biologicals, or acetazolamide), or in the previous 4 months; patients with a contraindication for any of the investigated drugs; patients who are cardiovascular unstable; patients who have a history of hyperthyroidism.